Streetbeat News

TSHA

Taysha Gene Therapies, Inc.

https://www.tayshagtx.com

Industry

Biotechnology

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.

Open

2.22

Mkt cap

434M

Volume

5.6M

High

2.28

P/E Ratio

3.37

52-wk high

4.32

Low

2.06

Div yield

N/A

52-wk low

1.19

Taysha Gene Therapies shares surged following the announcement of improved FY23 EPS results and updates on corporate and clinical developments.

Portfolio Pulse from Benzinga Newsdesk

March 20, 2024 | 12:29 pm

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) shares surged 27.1% in pre-market trading after reporting a significant year-over-year decrease in FY23 losses and providing positive clinical updates. Other stocks also showed notable pre-market movements, with several companies experiencing significant gains or losses due to various factors such as financial results, business updates, and public offerings.

Portfolio Pulse from Avi Kapoor

March 20, 2024 | 12:20 pm

Needham analyst Gil Blum maintains a Buy rating on Taysha Gene Therapies (NASDAQ:TSHA) and raises the price target from $5 to $7.

Portfolio Pulse from Benzinga Newsdesk

March 20, 2024 | 11:03 am

In Tuesday's after-market session, several healthcare stocks showed significant movement. Etao International Co led the gainers with a 249.4% increase, while Aquestive Therapeutics experienced the largest decline among the losers at 11.4%. Taysha Gene Therapies reported Q4 earnings, contributing to a 29.36% rise in its stock. Other notable movers include Moleculin Biotech, Turnstone Biologics, and Enveric Biosciences on the gainers' side, and Trxade Health, Ontrak, and Virpax Pharmaceuticals among the losers.

Portfolio Pulse from Benzinga Insights

March 19, 2024 | 9:34 pm

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) reported its FY23 results, showing a significant reduction in losses per share from $3.78 to 96 cents and an increase in cash reserves to $143.9 million. The company highlighted progress in its REVEAL Phase 1/2 trial, including expansion into the U.S. and promising safety and efficacy data. Shares surged 31.11% after-hours to $2.95.

Portfolio Pulse from Erica Kollmann

March 19, 2024 | 9:07 pm

Taysha Gene Therapies (NASDAQ:TSHA) reported Q4 earnings with an EPS of $0.92, beating estimates by 936% and showing a revenue increase of $1.10 million from the previous year. Despite past earnings misses, the company's share price increased by 26% following the last quarterly report.

Portfolio Pulse from Benzinga Insights

March 19, 2024 | 8:35 pm

Taysha Gene Therapies shares surged following the announcement of an increase in their FY23 EPS results compared to the previous year.

Portfolio Pulse from Benzinga Newsdesk

March 19, 2024 | 8:25 pm

Taysha Gene Therapies reported a significant improvement in its FY23 financial results, with EPS improving to $(0.96) from $(3.78) YoY. Revenue increased to $15.5 million, primarily from its Option Agreement with Audentes Therapeutics (Astellas Gene Therapies), focusing on Rett syndrome research. R&D expenses decreased to $56.8 million, and G&A expenses to $30.0 million, contributing to a reduced net loss of $111.6 million. The company ended the year with $143.9 million in cash, expecting to support operations into 2026.

Portfolio Pulse from Benzinga Newsdesk

March 19, 2024 | 8:03 pm

Earnings reports for March 19, 2024, include a mix of projected profits and losses across various sectors. Notable companies like Tencent Music, HUYA, Caleres, XPeng, and ZTO Express are among those reporting. The reports span from technology and retail to biotech and mining, indicating a broad market impact.

Portfolio Pulse from Benzinga Insights

March 19, 2024 | 10:06 am

Taysha Gene Therapies (NASDAQ:TSHA) is scheduled to release its quarterly earnings report on March 19, 2024, with an expected EPS of $-0.11. Despite past earnings misses, the company's stock has seen a significant increase, with a 173.66% rise over the last 52 weeks. Investors are hopeful for positive guidance for the next quarter.

Portfolio Pulse from Benzinga Insights

March 18, 2024 | 3:00 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.